CXCL10 and hemophagocytic syndrome: Previous studies found IP-10 elevating in HLH patients during the active phase and decreasing after chemotherapy and during recovery, and expression of IP-10 was enhanced in IFN-γ-activated macrophages in the liver, spleen, and bone marrow (27).